GCN2 kinase Activation by ATP-competitive Kinase Inhibitors. GCN2 kinase Activation by ATP-competitive Kinase Inhibitors

Purpose: Use next generation sequencing to determine which CRISPR knockouts confer resistance to EGFR inhibitors and to determine which cellular pathways get upregulated in response to neratinib. Overall design: Glioblastoma cell lines were transduced with the TKOv3 CRISPR KO library and treated with vehicle or neratinib for 14 or 21 days. Transcriptomic data was obtained by treating parental or GCN2-KO SF268 cells with neratinib for 0, 6, or 72 hours.